ASH: Roche Looks To Fixed-Duration Edge In Bispecifics Battle

 
• By Andrew McConaghie

Roche is highlighting the fixed-duration dosing benefits of Lunsumio and Columvi over AbbVie/Genmab’s Epkinly in B-cell lymphomas as they fight for market dominance. However, the speed at which the companies complete Phase III studies could also be a deciding factor.

Roche_Logo_Glass

More from ASH

More from Therapy Areas